Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2010
12/15/2010CN101283979B Preparation method of hyaluronic acid small fragment plaster for promoting the wound healing
12/15/2010CN101267837B Compositions for treatment of systemic mastocytosis
12/15/2010CN101264077B Lignans and its use for preparing antiphlogistic antiendotoxin medicaments
12/15/2010CN101255132B 6-aryl-3-substituted methylene-pyridinone derivatives and uses thereof
12/15/2010CN101254181B Hypertension-treating medicine combination
12/15/2010CN101249188B Chinese medicinal composition for curing critter bow-shaped vermination and preparation method and application thereof
12/15/2010CN101244105B Pseudo-ginseng standard extract P1237, its pharmaceutical combination, its preparing method and its uses
12/15/2010CN101239105B Chinese medicine for treating tinea pedis
12/15/2010CN101234140B Pharmaceutical composition for curing eczema and preparation and application thereof
12/15/2010CN101230015B Substituted cinnamic acid derivatives containing amine substituent group and tumor cytotoxicity thereof
12/15/2010CN101229174B Antianaphylaxis compound containing epinastine hydrochloride
12/15/2010CN101217960B Therapeutic agent and treatment method for ameliorating uremia
12/15/2010CN101204525B Tincture medicine for burn
12/15/2010CN101204474B Tincture medicine for wrick
12/15/2010CN101204444B Cataplasm for amygdalitis
12/15/2010CN101199795B Pediluvium medicament for treating tinnitus
12/15/2010CN101199704B External medicament for treating summer-heat furuncle sore
12/15/2010CN101199703B Tincture medicament for treating acne
12/15/2010CN101199643B Compound agent for cultivating German mirror carp non-specificity immunity and using method thereof
12/15/2010CN101199597B Traditional Chinese medicament for treating acute appendicitis
12/15/2010CN101194981B Powder medicament for treating otitis media chronica
12/15/2010CN101186633B Saponin antimycotic compounds in holothuria scabra jaeger and preparation method thereof
12/15/2010CN101186632B Method for preparing eleutheroside or aglycone thereof with anti-inflammatory action
12/15/2010CN101185671B Anti-tumor medicine extracted from Juglans regia and preparation method thereof
12/15/2010CN101181483B Chinese patent drug for curing cataptosis and hemiparalysis sequela
12/15/2010CN101181306B Nano-scale compound pearl dimension C lozenge and preparation method thereof
12/15/2010CN101180299B Acetylenyl-pyrazolo-pvrimidine derivatives as MGLUR2 antagonists
12/15/2010CN101177421B Method for preparing high-purity taxone compounds
12/15/2010CN101176722B Scutellaria glycosides freeze dried injection solution and preparation method thereof
12/15/2010CN101172959B N,N*-2[fluoroform (oxygen) group] substituted phenyl derivant of 4-methoxy-1,3-benzene diamide and uses of the same
12/15/2010CN101171238B (3,4-dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amines having an activity on the 5-HT receptor
12/15/2010CN101168551B lousewort lignans compounds, preparation method and application thereof
12/15/2010CN101164546B Vein-relaxing pain-relieving medicinal composition and preparation method and use thereof
12/15/2010CN101163703B Imidazo [1, 2-a]pyridine derivatives useful as peptide deformylase (pdf) inhibitors
12/15/2010CN101163688B A process for the purification of 10-deacetylbaccatine iii from 10-de acet yl-2- debenzoyl-2-pentenoylbaccatine iii
12/15/2010CN101161253B Pharmaceutical composition of melon betel or its extract and safflower or its extract
12/15/2010CN101153028B Compounds with antimicrobial antiviral activity
12/15/2010CN101148460B Azithromycin derivative and application thereof
12/15/2010CN101141959B 2,5-disubstituted phenyl methanone derivatives as glycine transporter 1 (Glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders
12/15/2010CN101138635B Fibrin glue vasodilation agent sustained-release long-acting composition
12/15/2010CN101125147B Glucosamine calcium medicine preparation, preparation method and application thereof
12/15/2010CN101120099B Method of inhibiting expression of target mRNA using sirna consisting of nucleotide sequence complementary to said target mRNA
12/15/2010CN101102766B Novel derivatives of porphyrin, particularly chlorins and/orbacteriochlorins, and uses thereof in photodynamic therapy
12/15/2010CN101096346B New naphthalene derivatives, method of preparing same and pharmaceutical compositions containing them
12/15/2010CN101090901B Hexahydropyridoisoqinolines as DPP-IV inhibitors
12/15/2010CN101084905B Application of ganoderic acid Me in tumoral growth or propagation inhibitor
12/15/2010CN101084220B Halogen substituted benzodiazepine derivatives
12/15/2010CN101076517B Substituted piperidines as modulators of dopamine neurotransmission
12/15/2010CN101076323B Medicine composition for treating fatmass
12/15/2010CN101062033B Medicine combination for treating inflammation of vagina
12/15/2010CN101054604B Application of oligonucleotide complemented with rna used as transcription product of gene
12/15/2010CN101052392B Orally administrable antimalarial combined preparation and preparation process thereof
12/15/2010CN101022797B Novel use of alpha-sympathomimetics having a 2-imidazoline structure
12/15/2010CN101012211B Substituted andrographolide derivative, preparing method and pharmaceutical compound thereof
12/15/2010CN101007017B Extract of traditional Chinese medicine having alpha-glucosidase inhibitor activity and its application
12/15/2010CN101006999B Therapeutic uses and compositions of isoflavones
12/15/2010CN100999517B Pyrazole formylamine derivate, its pharmaceutical composition and preparation process
12/14/2010USRE41998 topically administering to the site with sympatholytic agents for treating pain; with adrenergic antagonist, alpha -2-adrenergic agonist, or other drug that depletes or blocks synthesis of sympathetic norepinephrine; side effect reduction
12/14/2010USRE41996 Composition and methods for enhancing receptor-mediated cellular internalization
12/14/2010US7851654 Chalcone derivatives, pharmaceutically acceptable salt, method for preparation and uses thereof
12/14/2010US7851642 δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amide compound
12/14/2010US7851638 glycine transporter (GlyT1) inhibitors, such as 2,4-dichloro-N-({1-cyclopropylmethyl-4-[(1-methyl-1H-1,2,3-triazol-4-yl)sulfonyl]cyclohexyl}methyl)benzamide, useful in the treatment of neurological and psychiatric disorders associated with glutamatergic neurotransmission dysfunction
12/14/2010US7851637 Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
12/14/2010US7851636 {2-[3-Cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial; antidiabetic agents
12/14/2010US7851635 which comprises thiadiazoline derivatives, effective in treatment of a disease associated with cell proliferation, such as restenosis, cardiac hypertrophy and immunologic diseases
12/14/2010US7851634 enzyme inhibitors such as N-(2-Carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2-isopropyl-7-[3-(3-methoxypropyl)-1H-indol-5-ylmethyl]-8-methylnonanamide, used as hypotensive agents
12/14/2010US7851632 Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation
12/14/2010US7851631 Biphenyl compounds useful as muscarinic receptor antagonists
12/14/2010US7851630 Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
12/14/2010US7851629 4-(ortho,meta-disubstituted phenyl)-1-alkypiperidines, such as 4-(3-fluoro-2-methylphenyl)-1-propylpiperidine, used for the treatment of nervous system disorders
12/14/2010US7851626 4,4,5,5, tetrasubstituted imidazolines
12/14/2010US7851622 6-(4-Chlorophenyl)-3-(4-(2-hydroxy-2-methylpropoxy)-3-methoxyphenyl)-thieno[3,2-d][1,2,3]triazin-4(3H)-one, for example; for treating a patient suffering from an MCHR-1 modulated disease or disorder such as obesity, diabetes, depression or anxiety
12/14/2010US7851617 Indole derivatives
12/14/2010US7851615 Lipophilic conjugated iRNA agents
12/14/2010US7851602 Glucopyranosyl-substituted ((hetero)cycloalkylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
12/14/2010US7851599 Combination of an anti-ED—B fibronectin domain antibody—IL-2 fusion protein and gemcitabine
12/14/2010US7851592 Recombinant check point kinase for use in identifying modulator for use in treatment and prevention of cell proliferative disorders
12/14/2010US7851565 For pegylation of biodrugs and drugs; for example, polyethylene glycol with pyridyldithioalkoxy end groups; allows target amino acid for attachment, to be cysteine instead of lysine which can inactive some peptide drugs
12/14/2010US7851512 dosage form containing artemisinin1 part, piperaquine 3-9 parts primaquine up to 0.2 parts and adjuvants formulated into tablets or granules, suppositories, suspension syrup or dry powder for pediatric use
12/14/2010US7851510 Gossypol derivatives, production method thereof and uses of same
12/14/2010US7851509 Polymorphs of suberoylanilide hydroxamic acid
12/14/2010US7851508 Natural product derivatives with antimalarial activity
12/14/2010US7851507 Administering to a lung cancer patient 2-hydroxyoleic acid in an amount effective to inhabit proliferation of the cancer; leukemia, brain metastasis
12/14/2010US7851506 orally administering sodium oxybate a dosage form, to a patient, suffering from apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus
12/14/2010US7851505 for the treatment of diseases associated with aberrant vascularization, copper metabolism disorders, neurodegenerative disorders, obesity or nuclear factor kappa beta dysregulation
12/14/2010US7851504 a formulation containing 0.01% bimatoprost, about 200 ppm benzalkonium chloride, a phosphate buffer, NaCl, and water, pH 7.3; for ophthalmic administration; useful in treating glaucoma or ocular hypertension
12/14/2010US7851503 xanthocillin analogues such as 3,3'-Dimethoxyxanthocillin X dimethyl ether, used for increasing platelets in a human having a disease selected from thrombocytopenia caused by bone marrow grafting, surgery, infection, intestinal bleeding, anemia, myelodysplastic syndrome, and thrombopoietin deficiency
12/14/2010US7851502 Pharmaceutical formulations containing an SGLT2 inhibitor
12/14/2010US7851499 comprising 5-amino-1-(2,6,-dichloro-4-trifluoromethylphenyl)-4-trifluoromethylsulfinyl-3-cyanopyrazole, acetyl tributyl citrate, plant growth regulators and carriers, in the form of a stick, plate, tablet or particles
12/14/2010US7851498 cannabinoid receptor modulators such as 1-cyclohexyl-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid (adamantan-1-ylmethyl)-amide, used as dietetics, neuroprotectants, cognition activators, for treating diabetes, vision defects, psychological, respiratory system or gastrointestinal disorders
12/14/2010US7851496 Ionic liquid type crown ether derivatives, method for preparing the same and method for isolating metal ions using the same
12/14/2010US7851495 Thiophene-carboxamides useful as inhibitors of protein kinases
12/14/2010US7851494 administering 5-[(4-(2,6-difluorobenzyloxy)phenyl)-methyl]-1H-tetrazole for the treatment of insulin resistance, diabetes, hyperlipemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis
12/14/2010US7851493 Phenyl-1,2,4-oxadiazolone derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals
12/14/2010US7851492 Administering 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea activates an ERG channel; arrhythmia; cardiac ishemia, ishcemic heart disease, hypertrophic heart, cardiomyopathia or failing heart
12/14/2010US7851491 Modified bio-related substance, process for producing the same, and intermediate
12/14/2010US7851490 1-{1-[3-(2-Methoxy-pyridin-3-yl)-phenyl]-1 H-benzoimidazol-5-yl}-ethylamine, useful in the treatment of central nervous system diseases and disorders, and in particular for combating anxiety; anxiolytic agents
12/14/2010US7851489 N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; Met kinase inhibitor; hypatocyte growth factor antagonist; anticarcinogenic agent
12/14/2010US7851488 Tetrahydropyridines with central nervous system activity
12/14/2010US7851487 Use of tetrahydropyridines in the treatment of central nervous system disorders
1 ... 1961 1962 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 ... 7860